FBIO (Fortress Biotech, Inc.)

Insider Trading Activity

Every open-market purchase and sale reported by FBIO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Form 4 Filings
36
most recent
Open-Market Buys
4
code P
Sales
1
code S
Reporting Insiders
9
current holders
FBIO — Recent Form 4 Transactions (latest 2026-06-24)
FiledInsiderRole TypeSharesValue
2026-06-24 David Jin Chief Financial Officer A
2017-11-08 LINDSAY A MD ROSENWALD PRESIDENT, CEO Buy
2017-07-21 Dov Klein Director D
2017-07-21 Malcolm Hoenlein Director A
2017-07-21 Jimmie Harvey Director A
2017-01-27 MICHAEL S WEISS Exec. VC - Strategic Dev. A
2017-01-27 LINDSAY A MD ROSENWALD President and CEO MIXED
2017-01-24 Malcolm Hoenlein Director A
2017-01-24 Jimmie Harvey Director A
2017-01-24 Eric K Rowinsky Director A
2017-01-24 Dov Klein Director MIXED
2017-01-24 J JAY LOBELL Director A
2016-09-19 George Avgerinos SVP, Biologics Operations Sell
2016-09-16 George Avgerinos SVP, Biologics Operations A
2016-07-19 Dov Klein Director D
2016-06-17 LINDSAY A MD ROSENWALD President and CEO Buy
2016-03-28 Jimmie Harvey Director A
2016-03-28 Malcolm Hoenlein Director A
2016-01-05 MICHAEL S WEISS Exec. VC - Strategic Dev. A
2016-01-05 Eric K Rowinsky Director A
2016-01-05 Dov Klein Director A
2016-01-05 J JAY LOBELL Director A
2016-01-05 LINDSAY A MD ROSENWALD President and CEO A
2015-12-09 LINDSAY A MD ROSENWALD President and CEO Buy
2015-09-14 George Avgerinos SVP, Biologics Operations D
2015-09-10 George Avgerinos SVP, Biologics Operations D
2015-09-08 George Avgerinos SVP, Biologics Operations D
2015-09-04 George Avgerinos SVP, Biologics Operations D
2015-09-03 George Avgerinos SVP, Biologics Operations D
2015-09-02 George Avgerinos SVP, Biologics Operations D
2015-08-25 George Avgerinos SVP, Biologics Operations D
2015-08-21 George Avgerinos SVP, Biologics Operations D
2015-08-14 George Avgerinos SVP, Biologics Operations A
2015-07-17 George Avgerinos SVP, Biologics Operations D
2015-07-17 Dov Klein Director A
2015-06-03 LINDSAY A MD ROSENWALD President and CEO Buy
FBIO — Current Insider Holders
InsiderRole Shares HeldValue
Chief Financial Officer 1,651,571
Exec. VC - Strategic Dev. 533,411
Director 45,733
Director 23,333
SVP, Biologics Operations 19,533
Director 13,565
PRESIDENT, CEO 8,000
Director 3,667
Director 3,333
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the FBIO quote page; the site-wide leaderboard is on the insider transactions hub.